Source: Reuters
“Drugmaker Eli Lilly presented trial results to medical professionals on Saturday showing its next-generation obesity drug retatrutide curbed sleep apnea severity in addition to boosting weight loss and helping knee pain. In a Phase 3 trial, Lilly found a weekly injection of retatrutide reduced moderate-to-severe obstructive sleep apnea severity by 60.6% in adults with obesity. Lilly’s older drug Zepbound is approved for the condition. In the same trial, the drug reduced knee osteoarthritis pain by up to 73.1%, Lilly found. The results were presented at an American Diabetes Association conference in New Orleans.” (06/06/26)